Combination therapy vs. monotherapy in type 2 diabetes

Half of type 1 diabetes develops after 30 years of age

Glyxambi recommended for European approval to treat type 2 diabetes patients

21 Sept 2016

The combination drug Glyxambi, manufactured by Boehringer Ingelheim, has been recommended for European approval to treat adults with type 2 diabetes.

Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story

Top stories

Call for nominations for Awards Committee Chair
30 Oct 2024

James M Tanner Award - 2025 nominations open
30 Oct 2024

Would you like to host the BSPED annual meeting?
21 Oct 2024

Most read